KRAS and pachyonychia congenita: Results showed that PC patients within HRGcluster B subtype were more sensitive to 5‐fluorouracil, gemcitabine, cisplatin, erlotinib, irinotecan, KRAS(G12C) inhibitor, oxaliplatin, cyclophosphamide, paclitaxel, and sorafenib (Figures 5a, 5b, 5c, 5d, 5e, 5f, 5g, 5g, 5h, 5i, and 5k).